Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
34
PharmaCompass offers a list of Etoricoxib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Etoricoxib manufacturer or Etoricoxib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Etoricoxib manufacturer or Etoricoxib supplier.
PharmaCompass also assists you with knowing the Etoricoxib API Price utilized in the formulation of products. Etoricoxib API Price is not always fixed or binding as the Etoricoxib Price is obtained through a variety of data sources. The Etoricoxib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Etoricoxib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Etoricoxib, including repackagers and relabelers. The FDA regulates Etoricoxib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Etoricoxib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Etoricoxib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Etoricoxib supplier is an individual or a company that provides Etoricoxib active pharmaceutical ingredient (API) or Etoricoxib finished formulations upon request. The Etoricoxib suppliers may include Etoricoxib API manufacturers, exporters, distributors and traders.
click here to find a list of Etoricoxib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Etoricoxib DMF (Drug Master File) is a document detailing the whole manufacturing process of Etoricoxib active pharmaceutical ingredient (API) in detail. Different forms of Etoricoxib DMFs exist exist since differing nations have different regulations, such as Etoricoxib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Etoricoxib DMF submitted to regulatory agencies in the US is known as a USDMF. Etoricoxib USDMF includes data on Etoricoxib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Etoricoxib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Etoricoxib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Etoricoxib Drug Master File in Korea (Etoricoxib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Etoricoxib. The MFDS reviews the Etoricoxib KDMF as part of the drug registration process and uses the information provided in the Etoricoxib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Etoricoxib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Etoricoxib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Etoricoxib suppliers with KDMF on PharmaCompass.
A Etoricoxib written confirmation (Etoricoxib WC) is an official document issued by a regulatory agency to a Etoricoxib manufacturer, verifying that the manufacturing facility of a Etoricoxib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Etoricoxib APIs or Etoricoxib finished pharmaceutical products to another nation, regulatory agencies frequently require a Etoricoxib WC (written confirmation) as part of the regulatory process.
click here to find a list of Etoricoxib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Etoricoxib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Etoricoxib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Etoricoxib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Etoricoxib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Etoricoxib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Etoricoxib suppliers with NDC on PharmaCompass.
Etoricoxib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Etoricoxib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Etoricoxib GMP manufacturer or Etoricoxib GMP API supplier for your needs.
A Etoricoxib CoA (Certificate of Analysis) is a formal document that attests to Etoricoxib's compliance with Etoricoxib specifications and serves as a tool for batch-level quality control.
Etoricoxib CoA mostly includes findings from lab analyses of a specific batch. For each Etoricoxib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Etoricoxib may be tested according to a variety of international standards, such as European Pharmacopoeia (Etoricoxib EP), Etoricoxib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Etoricoxib USP).
